Last updated: February 19, 2026
Almirall is a Spanish pharmaceutical company focused on dermatology. Its market position is defined by its specialized product portfolio, geographic presence, and R&D pipeline. The company's strengths lie in its established dermatological franchises, particularly in psoriasis and actinic keratosis. Strategic insights indicate a focus on consolidating its leadership in medical dermatology and exploring new therapeutic areas within the specialty.
What Is Almirall's Core Therapeutic Focus?
Almirall's core therapeutic focus is dermatology. This specialization encompasses a range of skin conditions, with a particular emphasis on chronic and inflammatory diseases. The company's product development and commercialization efforts are concentrated within this medical segment.
Key Dermatological Areas of Focus:
- Psoriasis: Almirall has a significant presence in the psoriasis market, offering treatments for this chronic autoimmune condition.
- Actinic Keratosis (AK): The company holds a strong position in the treatment of AK, a precancerous skin lesion.
- Other Inflammatory Skin Diseases: Almirall also targets other inflammatory dermatological conditions, aiming to address unmet medical needs.
- Acne: The company has also developed treatments for acne.
How Is Almirറോll Structured Geographically and Commercially?
Almirall operates primarily in Europe, with a strategic presence in select international markets. Its commercial structure is designed to support the marketing and sales of its dermatological products across these regions.
Geographic Market Presence:
- Europe: This is Almirall's primary market, with established operations in key countries including Spain, Germany, France, Italy, and the United Kingdom.
- United States: The company has a presence in the U.S. market, focusing on specific dermatological indications.
- Other International Markets: Almirall also engages in licensing agreements and partnerships to extend its reach in other regions.
Commercialization Strategy:
Almirall employs a direct sales force for key European markets, complemented by partnerships and distribution agreements for other territories. The company's commercial approach emphasizes medical education and support for healthcare professionals specializing in dermatology.
What Are Almirall's Key Products and Their Market Performance?
Almirall's product portfolio is centered on established brands and pipeline candidates within dermatology. Performance varies by product and market.
Leading Products and Indications:
- Ilumya (tirilazolumab): A biologic treatment for moderate to severe plaque psoriasis. In 2023, Ilumya sales reached €274.3 million, a 9% increase compared to 2022. [1] This product represents a significant driver of Almirall's growth.
- Skilarence (dimethyl fumarate): An oral treatment for moderate to severe plaque psoriasis. Sales for Skilarence were €198.7 million in 2023, an increase of 13% over 2022. [1] Skilarence contributes substantially to Almirall's psoriasis franchise.
- Picato (ingenol mebutate): A topical treatment for actinic keratosis. Picato's sales have been impacted by market dynamics and regulatory reviews in various regions. In 2023, Picato generated €19.9 million in revenue. [1]
- Enstilar (calcipotriol/betamethasone dipropionate): A foam-based combination therapy for plaque psoriasis. Enstilar sales were €86.2 million in 2023, a decrease of 5% from 2022. [1]
- Klerna (calcipotriol): Another treatment for plaque psoriasis. Klerna generated €51.8 million in revenue in 2023, a 4% increase. [1]
What Is Almirall's Research and Development (R&D) Pipeline?
Almirall's R&D pipeline is focused on advancing its dermatological franchises and exploring new therapeutic opportunities. The pipeline includes both preclinical and clinical-stage assets.
Pipeline Highlights:
- Lebrikizumab: A monoclonal antibody targeting IL-13 for atopic dermatitis and moderate-to-severe plaque psoriasis. Almirall has a collaboration with Eli Lilly and Company for this compound. [2] In early 2024, regulatory submissions were anticipated in the EU and US. [3]
- Other Early-Stage Assets: Almirall continues to invest in the discovery and development of novel compounds for various dermatological conditions, including rare diseases.
What Are Almirall's Financial Performance Indicators?
Almirall's financial performance is characterized by revenue growth driven by key dermatological products, alongside investments in R&D and commercial expansion.
Key Financial Metrics (2023):
- Net Sales: €936.9 million. [1]
- EBITDA: €180.4 million. [1]
- Net Profit: €44.5 million. [1]
- R&D Investment: €173.6 million, representing 18.5% of net sales. [1]
What Are Almirall's Competitive Strengths?
Almirall possesses several competitive strengths that underpin its position in the pharmaceutical market.
Key Strengths:
- Dermatology Specialization: A deep understanding of the dermatology market, patient needs, and physician prescribing habits.
- Established Product Portfolio: A range of well-recognized and prescribed treatments for significant dermatological conditions like psoriasis and actinic keratosis.
- European Market Presence: Strong infrastructure and market access in key European countries.
- Pipeline Development: A focused R&D pipeline with promising candidates like lebrikizumab.
- Scientific Expertise: Accumulated knowledge and talent in dermatological research and development.
What Are the Key Challenges Facing Almirall?
Almirall navigates several challenges inherent to the pharmaceutical industry, particularly within a specialized therapeutic area.
Primary Challenges:
- Competition: Intense competition from both large pharmaceutical companies and smaller, specialized firms offering novel therapies.
- Pricing Pressures: Increasing scrutiny on drug pricing and reimbursement policies in various markets.
- R&D Risk: The inherent uncertainty and high cost associated with drug development, including clinical trial failures.
- Market Exclusivity: The eventual loss of market exclusivity for key products due to patent expirations.
- Regulatory Hurdles: Navigating complex and evolving regulatory landscapes for drug approval and marketing.
What Are Almirall's Strategic Priorities?
Almirall's strategic priorities are geared towards consolidating its market leadership, expanding its R&D capabilities, and optimizing its operational efficiency.
Strategic Objectives:
- Strengthening Medical Dermatology Franchise: Continued investment in and promotion of key dermatological products, particularly Ilumya and Skilarence.
- Advancing R&D Pipeline: Progressing lead candidates like lebrikizumab through clinical development and regulatory approvals.
- Geographic Expansion and Partnerships: Exploring opportunities to expand its market reach and engage in strategic collaborations.
- Operational Excellence: Enhancing efficiency in manufacturing, supply chain, and commercial operations.
- Digital Transformation: Leveraging digital tools to improve patient engagement, data analytics, and commercial effectiveness.
What Is the Outlook for Almirall?
The outlook for Almirall is contingent on the successful advancement of its R&D pipeline, continued performance of its commercialized products, and its ability to adapt to evolving market dynamics.
Outlook Factors:
- Pipeline Success: The regulatory approval and market uptake of lebrikizumab will be a significant factor.
- Market Dynamics: The competitive landscape for psoriasis and atopic dermatitis treatments will influence market share.
- Economic Conditions: Broader economic factors may impact healthcare spending and drug access.
- Regulatory Environment: Changes in pricing regulations or approval pathways could affect growth.
Key Takeaways
Almirall is a focused dermatology player with a strong European presence. Ilumya and Skilarence are key revenue drivers, with lebrikizumab representing a significant pipeline opportunity. The company faces competition and pricing pressures, necessitating continued innovation and strategic market execution.
Frequently Asked Questions
-
What is Almirall's primary source of revenue?
Almirall's primary source of revenue comes from its portfolio of dermatological treatments, with Ilumya and Skilarence being the leading contributors.
-
When is the expected approval timeline for lebrikizumab?
Regulatory submissions for lebrikizumab in the EU and US were anticipated in early 2024, with subsequent approval timelines depending on regulatory review processes.
-
Does Almirall have any other therapeutic areas besides dermatology?
While Almirall's core focus is dermatology, it has historically explored other areas. However, its current strategy is heavily concentrated on skin diseases.
-
What is Almirall's market capitalization?
As of early 2024, Almirall's market capitalization fluctuates based on stock market performance, but it is typically valued in the billions of Euros. Specific figures require real-time market data.
-
How does Almirall manage patent expiries for its key products?
Almirall manages patent expiries through a combination of developing next-generation therapies, seeking patent extensions where applicable, and exploring lifecycle management strategies for its existing products.
Citations
[1] Almirall. (2024, February 28). Almirall presents its 2023 full-year results: Revenue of €937 million, EBITDA of €180 million and Net Profit of €44 million. [Press release]. Retrieved from https://www.almirall.com/media/press-releases/almirall-presents-its-2023-full-year-results
[2] Almirall. (n.d.). Lebrikizumab. Retrieved from https://www.almirall.com/r-d/pipeline/lebrikizumab
[3] Eli Lilly and Company. (2023, November 16). Lilly and Almirall announce submission of marketing authorisation application to the European Medicines Agency for lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. [Press release]. Retrieved from https://investor.lilly.com/news-events/press-releases/press-release-details/2023/Lilly-and-Almirall-Announce-Submission-of-Marketing-Authorisation-Application-to-the-European-Medicines-Agency-for-lebrikizumab-for-the-Treatment-of-Moderate-to-Severe-Atopic-Dermatitis/default.aspx
